• Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA issued a complete response letter for the firm's supplemental new drug application for Xarelto (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome. Janssen is evaluating the letter and said it will respond to the agency's questions.